Abrocitinib


Abrocitinib is a Janus kinase inhibitor drug which is currently under investigation for the treatment of atopic dermatitis. It was developed by Pfizer.

Side effects

The most common adverse effects in studies were upper respiratory tract infection, headache, nausea, and diarrhea.

Pharmacology

Mechanism of action

It is a selective inhibitor of the enzyme janus kinase 1.

Pharmacokinetics

Abrocitinib is quickly absorbed from the gut and generally reaches highest blood plasma concentrations within one hour. Only 1.0 to 4.4% of the dose are found unmetabolized in the urine.

Timeline